Download PDF
Thromb Haemost 1978; 39(02): 437-449
DOI: 10.1055/s-0038-1646703
Original Article
Schattauer GmbH Stuttgart

The Measurement of Human Plasma Antiplasmin Activity by Radial Diffusion Assay

W A Andes
The Oxford Haemophilia Centre, Churchill Hospital, Oxford, England
› Author Affiliations
Further Information

Publication History

Received 15 May 1977

Accepted 16 September 1977

Publication Date:
26 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

An assay of human antiplasmins has been developed utilizing radial diffusion of plasma from wells cut in plasmin-enriched, fibrinogen-agarose plates. After diffusion the fibrinogen is clotted. Zones of fibrin protected from background fibrinolysis develop as the result of plasma antiplasmin activity. A pooled plasma standard was taken to contain 100 % antiplasmin activity. Antiplasmin activity of 52 normal subjects varied from 64 to 132 %. Washed platelets contained 1-5 % antiplasmin activity. Using antisera to precipitate individual inhibitors, physical methods of separation, and electrophoresis of plasma in agarose, several different proteins were found to have antiplasmin activity in this assay. Thus, α2-macroglobulin contributed 56%, α1-antitrypsin 20%, antithrombin III 2%, and other proteins 22% of the total antiplasmin activity. 1 ml of whole plasma neutralized 7.0 CTA units of plasmin.

 

  • References

  • 1 Andes WA, Lindberg RB, Mceuen DD, Baron JP. 1976; Inhibition of fibrinolysis in the burned infected rat: antiplasmin induced by burn wound infection. Thrombosis and Haemostasis 36: 173
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Cooper KE. 1963. The theory of antibiotic inhibition zones. In: Kavangh F. (Ed.) Analytical Microbiology. Academic Press; London:
    Google Scholar
  • 3 Gallimore MJ. 1975; Serum inhibitors of fibrinolysis. British Journal of Haematology 31: 217
    CrossrefPubMedGoogle Scholar
  • 4 GALLUS AS, Hirsh J, Gent M. 1973; Relevance of preoperative and postoperative blood tests to postoperative leg-vein thrombosis. Lancet II: 805
    PubMedGoogle Scholar
  • 5 Harpel PC, Mosesson MW. 1973; Degradation of human fibrinogen by plasma α-2-macro-globulin-enzyme complexes. Journal of Clinical Investigation 52: 2175
    CrossrefPubMedGoogle Scholar
  • 6 Hedner U. 1973; Studies on an inhibitor of plasminogen activation in human serum. Thrombosis et Diathesis Haemorrhagica 30: 414
    PubMedGoogle Scholar
  • 7 Hedner U. 1974. Thrombosis: Pathogenesis and clinical trials. In: Deutsch E, Brinkhous KM, Lechner K, Hinnon S. Transactions of the plenary sessions, IV International Congress on Thrombosis and Haemostasis; New York:
    Google Scholar
  • 8 Hedner U, Collen D. 1976; Immunochemical distinction between the inhibitors of plasminogen activation and antiplasmin in human plasma. Thrombosis Research 8: 875
    CrossrefPubMedGoogle Scholar
  • 9 Highsmith RF, Rosenberg RD. 1974; The inhibition of human plasmin by human antithrombin-heparin cofactor. Journal of Biological Chemistry 249: 4335
    PubMedGoogle Scholar
  • 10 Jacobsen CD. 1964; The caseinolytic method for determination of plasminogen-plasmin in human plasma and serum. Scandinavian Journal of Clinical and Laboratory Investigation 16: 372
    CrossrefPubMedGoogle Scholar
  • 11 Kaelin AC. 1975; Sodium periodate modification of factor VIII procoagulant activity. British Journal of Haematology 31: 349
    CrossrefPubMedGoogle Scholar
  • 12 Kirkwood TBL, Campbell PJ, Gaffney PJ. 1975; A standard for human plasmin. Thrombosis et Diathesis Haemorrhagica 34: 20
    PubMedGoogle Scholar
  • 13 Lane JL, Bird P, Rizza CR. 1975; A new assay for the measurement of total progressive antithrombin. British Journal of Haematology 30: 103
    CrossrefPubMedGoogle Scholar
  • 14 Laurell CB. 1972; Electroimmunoassay. Scandinavian Journal of Clinical and Laboratory Investigation 29 Suppl (Suppl. 124) 2
    PubMedGoogle Scholar
  • 15 Miller-Andersson M, Borg H, Andersson LO. 1974; Purification of antithrombin III by affinity chromatography. Thrombosis Research 5: 439
    CrossrefPubMedGoogle Scholar
  • 16 Murray J, Crawford GPM, Ogston D, Douglas AS. 1974; Studies on an inhibitor of plasminogen activators in human platelets. British Journal of Haematology 26: 661
    CrossrefPubMedGoogle Scholar
  • 17 Naeye RL. 1961; Thrombotic disorders with increased levels of antiplasmin and antiplasminogen. New England Journal of Medicine 265: 867
    CrossrefPubMedGoogle Scholar
  • 18 Niléhn JE, Ganrot PO. 1967; Plasmin, plasmiri inhibitors and degradation products of fibrinogen in human serum during and after intravenous infusion of streptokinase. Scandinavian Journal of Clinical and Laboratory Investigation 20: 113
    CrossrefPubMedGoogle Scholar
  • 19 Norman PS, Hill BM. 1958; Studies of the plasmin system. III. Physical properties of two plasmin inhibitors. Journal of Experimental Medicine 108: 639
    CrossrefPubMedGoogle Scholar
  • 20 Pizzo SU, Schwartz ML, Hill RL, Mckee PA. 1972; Mechanism of ancrod anticoagulation: A direct proteolytic effect on fibrin. Journal of Clinical Investigation 51: 2841
    CrossrefPubMedGoogle Scholar
  • 21 Schmer G, Krys J. 1974; A solid-phase radioassay for plasminogen in human plasma. Journal of Laboratory and Clinical Medicine 83: 153
    PubMedGoogle Scholar
  • 22 Schmer G, Branson HE. 1975; A solid-phase radioassay for the quantitative determination of antiplasmin activity in human plasma. British Journal of Haematology 30: 117
    CrossrefPubMedGoogle Scholar
  • 23 Sgouris JT, Inman JK, Mccall KB, Hyndman LA, Anderson HD. 1960; The preparation of human fibrinolysin (Plasmin). Vox Sanguinis 5: 357
    CrossrefPubMedGoogle Scholar
  • 24 WALSH PN. 1972; Albumin Density Gradient Separation and Washing of Platelets and the Study of Platelet Coagulant Activities. British Journal of Haematology 22: 205
    CrossrefPubMedGoogle Scholar
  • 25 Wiman B, Wallen P. 1973; Activation of human plasminogen by an insoluble derivative of urokinase. European Journal of Biochemistry 36: 25
    CrossrefPubMedGoogle Scholar